Identification and characterization of post-translational modifications: Clinical implications

Juliane Hermann, Leon Schurgers, Vera Jankowski*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Post-translational modifications (PTMs) generate marginally modified isoforms of native peptides, proteins and lipoproteins thereby regulating protein functions, molecular interactions, and localization. With a key role in functional proteomics, post-translational modifications are recently also associated with the onsets and progressions of various diseases, such as cancer, cardiovascular, renal, and metabolic diseases. With the impact of post-translational modifications becoming increasingly clear, its reliable detection and quantification remain a major obstacle in the translation of these novel pathological markers into clinical diagnosis. While current antibody-based clinical diagnostics struggle to detect and quantify these marginal protein and lipoprotein alterations, state-of-the-art mass spectrometric, proteomic approaches provide the mass accuracy and resolving power necessary to isolate, identify and quantify novel and pathological post-translational modifications; however clinical translation of mass spectrometric applications are still facing major challenges. Here we review the status quo of the clinical translation of mass-spectrometric applications as novel diagnostic tools for the identification and quantification of post-translational modifications and focus on the emerging role of mass spectrometric methods in the clinical assessment of PTMs in disease states.

Original languageEnglish
Article number101066
Number of pages7
JournalMolecular Aspects of Medicine
Volume86
Early online date12 Jan 2022
DOIs
Publication statusPublished - Aug 2022

Fingerprint

Dive into the research topics of 'Identification and characterization of post-translational modifications: Clinical implications'. Together they form a unique fingerprint.

Cite this